Model Vaccines Exploiting Fungal Mannosylation

利用真菌甘露糖基化的模型疫苗

• 批准号: 6963242
• 负责人: Stuart Michael Levitz
• 金额: $ 30.79万
• 依托单位: BOSTON MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-06-20 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6963242
• 关键词: Cryptococcus neoformans; T lymphocyte; antigen presentation; cellular immunity; clinical research; dendritic cells; endocytosis; fungal proteins; genetically modified animals; glycosylation; human subject; immune response; laboratory mouse; mannose; ovalbumin; protein structure function; receptor binding; recombinant proteins; tissue /cell culture; transfection /expression vector; vaccine development; vaccine evaluation; vector vaccine

DESCRIPTION (provided by applicant): Mannoproteins (MP) from Cryptococcus neoformans elicit strong T cell-mediated immune responses. Cryptococcal MP contain serine/threonine (S/T)-rich regions which serve as sites for extensive O-linked glycosylation as well as N-X-S/T sequons that serve as N-glycosylation sites. N-linked and O-linked glycans on yeasts are terminally mannosylated whereas fully processed mammalian glycoproteins rarely have terminal mannose groups. Mannose receptors (MR) on dendritic cells (DC) bind to MP, resulting in the efficient uptake, processing and presentation of peptide fragments of MP by DC. Given these findings, we hypothesize that the capacity of mannosylation to increase immunogenicity can be exploited to make recombinant vaccines that stimulate T-cell responses. To test this hypothesis, the capacity of differentially glycosylated preparations of the model antigen, ovalbumin (OVA), to elicit MHC Class I (CD8) and class II (CD4)-restricted T cell responses will be tested in vitro and in vivo. There are 3 specific aims: Aim 1 is to generate recombinant OVA preparations in bacterial, yeast, and mammalian cell vectors. Such preps should be unglycosylated, terminally mannosylated, and glycosylated but without terminal mannose groups, respectively. Addition of S/T-rich regions and N-to-Q substitutions will permit study of the relative contribution of O- and N-linkages to immunogenicity. The OVA preparations generated in aim 1 will be utilized in aim 2 to examine the effects of OVA glycosylation patterns on antigen uptake, processing and presentation in vitro, and in aim 3 to test the efficacy of the various glycosylated recombinant proteins to induce an immune response in vivo. Thus, Class I and Class ll-restricted responses to antigens that contain identical protein cores but that qualitatively and quantitatively differ with regards to glycosylation will be compared. The role of MR on DC as endocytic receptors allowing for the efficient capture of mannosylated OVA preparations will be studied using blockers of the MR and with knockout mice. Completion of these studies should add significantly to our knowledge of how innate recognition of foreign glycosylation patterns triggers adaptive immune responses and could suggests novel strategies for increasing the immunogenicity of vaccines.

描述（由申请方提供）：来自新型隐球菌的甘露糖蛋白（MP）引发强烈的T细胞介导的免疫应答。隐球菌MP含有富含丝氨酸/苏氨酸（S/T）的区域，其作为广泛的O-连接糖基化位点，以及N-X-S/T序列子，其作为N-糖基化位点。酵母上的N-连接和O-连接聚糖是末端甘露糖基化的，而完全加工的哺乳动物糖蛋白很少具有末端甘露糖基。树突状细胞（DC）上的甘露糖受体（MR）与MP结合，导致DC有效地摄取、加工和呈递MP的肽片段。鉴于这些发现，我们假设可以利用甘露糖基化增加免疫原性的能力来制备刺激T细胞应答的重组疫苗。为了检验这一假设，将在体外和体内测试模型抗原卵清蛋白（OVA）的差异糖基化制剂引发MHC I类（CD 8）和II类（CD 4）限制性T细胞应答的能力。有3个具体目标：目标1是在细菌、酵母和哺乳动物细胞载体中产生重组OVA制剂。这样的制备物应该分别是未糖基化的、末端甘露糖基化的和糖基化的但没有末端甘露糖基团。添加富含S/T的区域和N-至-Q取代将允许研究O-和N-键对免疫原性的相对贡献。目的1中生成的OVA制剂将用于目的2中，以检查OVA糖基化模式对体外抗原摄取、加工和呈递的影响，并用于目的3中，以检测各种糖基化重组蛋白在体内诱导免疫应答的功效。因此，将比较对含有相同蛋白质核心但在糖基化方面定性和定量不同的抗原的I类和II类限制性应答。将使用MR阻断剂和基因敲除小鼠研究MR作为内吞受体对DC的作用，从而有效捕获甘露糖基化OVA制剂。这些研究的完成将大大增加我们对外源糖基化模式的先天识别如何触发适应性免疫应答的认识，并可能提出增加疫苗免疫原性的新策略。